Patents by Inventor Joseph P. Buyniski

Joseph P. Buyniski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4600578
    Abstract: Oral administration of particular quaternized vinylimidazole-ethylene glycol dimethacrylate copolymers inhibits diarrhea.
    Type: Grant
    Filed: May 11, 1984
    Date of Patent: July 15, 1986
    Assignee: Bristol-Myers Company
    Inventors: Anthony W. Pircio, Joseph P. Buyniski, William T. Comer
  • Patent number: 4444777
    Abstract: Supra-additive blood platelet antiaggregation activity is observed with anagrelide in combination with those non-steroidal anti-inflammatory agents which are inhibitors of platelet cyclooxygenase. The supra-additive effects of such combinations make possible new compositions and methods for both therapeutic and prophylactic treatment of thrombosis and other disorders associated with blood platelet aggregation.
    Type: Grant
    Filed: August 5, 1983
    Date of Patent: April 24, 1984
    Assignee: Bristol-Myers Company
    Inventors: James S. Fleming, Jr., Joseph P. Buyniski
  • Patent number: 4432980
    Abstract: Supra-additive blood platelet antiaggregation activity is observed with anagrelide in combination with those non-steroidal anti-inflammatory agents which are inhibitors of platelet cyclooxygenase. The supra-additive effects of such combinations make possible new compositions and methods for both therapeutic and prophylactic treatment of thrombosis and other disorders associated with blood platelet aggregation.
    Type: Grant
    Filed: August 19, 1982
    Date of Patent: February 21, 1984
    Assignee: Bristol-Myers Company
    Inventors: James S. Fleming, Jr., Joseph P. Buyniski
  • Patent number: 4357330
    Abstract: Supra-additive blood platelet antiaggregation activity is observed with anagrelide in combination with those non-steroidal anti-inflammatory agents which are inhibitors of platelet cyclooxygenase. The supra-additive effects of such combinations make possible new compositions and methods for both therapeutic and prophylactic treatment of thrombosis and other disorders associated with blood platelet aggregation.
    Type: Grant
    Filed: July 30, 1981
    Date of Patent: November 2, 1982
    Assignee: Bristol-Myers Company
    Inventors: James S. Fleming, Jr., Joseph P. Buyniski
  • Patent number: 4339439
    Abstract: Enhanced antiulcer activity is obtained in warm-blooded animals by the concomitant administration of the histamine H.sub.2 -receptor antagonist, etintidine, and the pepsin complexing agent, pepstatin. Concomitant administration of the two entities reduces the amount of etintidine necessary for effective treatment, thereby decreasing its side effect liability.
    Type: Grant
    Filed: January 19, 1981
    Date of Patent: July 13, 1982
    Assignee: Bristol-Myers Company
    Inventors: Joseph P. Buyniski, Robert L. Cavanagh, Maxwell Gordon
  • Patent number: 4322427
    Abstract: A method of producing analgesia by the simultaneous or sequential administration of butorphanol and zomepirac and compositions comprising butorphanol and zomepirac which provide enhanced (synergistic) analgetic potencies.
    Type: Grant
    Filed: April 16, 1981
    Date of Patent: March 30, 1982
    Assignee: Bristol-Myers Company
    Inventors: Joseph P. Buyniski, Anthony W. Pircio
  • Patent number: 4277605
    Abstract: 3-Hydroxy-7-oxomorphinans and 3-hydroxy-7-oxoisomorphinans, optionally substituted on the 17-nitrogen atom, are potent, orally active antidiarrheal agents.
    Type: Grant
    Filed: March 7, 1980
    Date of Patent: July 7, 1981
    Assignee: Bristol-Myers Company
    Inventors: Joseph P. Buyniski, John W. Hooper, Gary M. F. Lim